-
13 May 2025 12:54:14
- Source: Sharecast
13 May 2025
Belluscura plc
("Belluscura" or the "Company")
Response to Share Price Movement
Belluscura plc (AIM: BELL), a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies, notes the recent movements in its share price.
On Friday 9 May 2025 the Company issued a notification which included, inter alia, a comprehensive trading update and commencement of strategic review. There have been no notifiable developments since the publication of that announcement. As stated in that notification, the Company will provide further updates as and when appropriate.
Enquiries:
For further information please contact:
|
Belluscura plc |
Tel: +44 (0)20 3128 8100 |
|
Paul Tuson, Chairman Robert Rauker, Chief Executive Officer
|
|
|
SPARK Advisory Partners Limited Nominated Adviser |
Tel: +44 (0)20 3368 3550 |
|
Neil Baldwin / Jade Bayat
|
|
|
Dowgate Capital Limited Joint Broker |
Tel: +44 (0)20 3903 7715 |
|
James Serjeant / Colin Climie (Sales and Corporate Broking) Russell Cook / Daniel Ingram (Corporate Finance) |
|
|
|
|
|
Allenby Capital Ltd Joint Broker |
Tel: +44 (0)20 3328 5656
|
|
Guy McDougall / Amrit Nahal (Sales and Corporate Broking) Jeremy Porter / Lauren Wright (Corporate Finance)
|
|
|
MHP Financial PR & Investor Relations |
Tel: +44 (0)20 3128 8100 email: Belluscura@mhpgroup.com |
|
Katie Hunt/Matthew Taylor |
|
For further information, please visit https://ir.belluscura.com/
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.